The incidence of BIA-ALCL is rare but varies depending on the type of implant. According to the FDA, the majority of cases occur in patients with textured implants, suggesting a potential link between the implant texture and the development of the lymphoma. Current estimates suggest the risk is approximately 1 in 3,000 to 1 in 30,000 in women with textured breast implants.
